Post Translational Medicines
Post Translational Medicines (PTM) is a San Francisco-based early-stage biotech decoding the 'dark proteome'.
About
Post Translational Medicines (PTM) is a San Francisco-based early-stage biotech decoding the 'dark proteome'. Its Surveyor platform combines next-generation proteomics, computational modeling and AI to map and drug proteoforms shaped by post-translational modifications, targeting first-in-class therapies for age-related diseases and cancer. It is part of the SOSV/IndieBio San Francisco program (IBSF 25H2).
Capital graph
Founders / team· 2
Comparable companies· by market
This company
BusinessLatest roundTotal raisedDate- Post Translational Medicines
Post Translational Medicines (PTM) is a San Francisco-based early-stage biotech decoding the 'dark proteome'. Its Surveyor platform combines next-generation proteomics, computational modeling and AI to map and drug proteoforms shaped by post-translational modifications, targeting first-in-class therapies for age-related diseases and cancer. It is part of the SOSV/IndieBio San Francisco program (IBSF 25H2).
—
United States
BusinessLatest roundTotal raisedDate- RyboDyn
AI-driven sequencing and discovery platform decoding the "dark proteome" to find cancer-specific cryptic targets in patient tumors that conventional methods miss, for first-in-class cancer immunotherapies
Seed · $14M · 2026-03
$14M - Escalante
Drug discovery and diagnostics platform combining AI with single-molecule proteomics
$7M
$7M - Neomera BioLab
AI-driven peptide/biologics drug discovery platform targeting hard-to-drug membrane protein targets such as GPCRs and ion channels, with an in-house pipeline including non-opioid analgesics.
—
China
BusinessLatest roundTotal raisedDate- Convergen
TRIM21-based TrimTAC targeted protein degradation platform for therapies clearing pathological protein aggregates; pipeline focused on neurodegenerative and autoimmune diseases
Seed · $25M · 2026-08
$25M - NeuShen Therapeutics
Novel drugs for CNS psychiatric and neurological disorders, with the NeuChime small-molecule discovery platform and NeuGem AAV gene therapy platform; lead programs include NS-136 (M4 positive allosteric modulator) and NS-041 (KCNQ2/3 activator)
Series B · 2026-09
— - Levinthal Biotech
AI protein design services, with the proprietary all-atom protein design platform Pallatom
Series A · $14M · 2025-12
$14M
Europe
BusinessLatest roundTotal raisedDate- CardiaTec
Uses AI and large-scale multi-omics data to discover new therapies for cardiovascular disease
Seed · $7M · 2024-09
$7M - Isomorphic Labs
AI-driven drug design platform (IsoDDE engine): uses AlphaFold-based technology to predict protein structures and design new drug molecules; builds its own therapeutic pipeline and conducts joint R&D with large pharmaceutical companies
Series B · $2.7B · 2026-05
$2.7B - Sightera Biosciences
AI-native drug discovery: patient-derived disease models and generative AI to design small-molecule cancer/fibrosis therapies
Pre-Seed · $3M · 2026-07
$3M
Other / unspecified
BusinessLatest roundTotal raisedDate- 深度细胞
Combines AI with multiscale molecular physics to build a "virtual cell world model" for disease mechanism discovery and drug design
Seed · $14M · 2026-08
$14M - Galux
AI plus physics-based protein/antibody design platform (GaluxDesign) for drug discovery
Series B · $58M · 2026-02
$58M - Gero
Biotech targeting aging and chronic disease
Series A · $6M · 2023-10
$6M
Confirmed rounds only. Matched on subsector, sector, stage and funding scale — each verifiable on the company profiles.
Investors that may fit
Andreessen Horowitz
25 Life Sciences deals in the last 24 months · 23 in Silicon Valley
Request intro →Ranked by each firm’s deals in this sector over the last 24 months, weighted by nearby stage and shared geography. Indicative only — no rating judgment.